Results 161 to 170 of about 26,025 (223)

Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold? [PDF]

Cancers (Basel)
Schreiber J, Hopfinger G, Gleixner KV.
europepmc   +1 more source

Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH).

Blood
Kaddoura M, Wiedmeier-Nutor JE, Gupta VA, Jelinek T, Ziccheddu B, Shivaram S, Tang H, Owens RW, Sevcikova T, Fonseca R, Durante M, Diamond B, Zhao L, Zhu YX, Shi CX, Matulis SM, Mitsiades CS, Landgren O, Usmani S, Hajek R, Chesi M, Bergsagel PL, Braggio E, Boise LH, Fonseca R, Kumar S, Maura F, Baughn LB.   +27 more
europepmc   +1 more source

FOXM1 inhibitor, RCM‑1, enhances venetoclax mediated apoptosis through downregulation of ATP2B4 in rhabdomyosarcoma. [PDF]

Int J Oncol
Merjaneh N, Lan YW, Deng Z, Donovan J, Wang G, Do J, Juan T, Xia X, Kalinichenko VV, Kalin TV.   +9 more
europepmc   +1 more source

Venetoclax-based low-intensity therapy in pediatric AML: A viable option for chemotherapy-intolerant patients. [PDF]

Am J Blood Res
Dhariwal N, Srinivasan S.
europepmc   +1 more source

Impact of venetoclax trough levels on safety and efficacy in the treatment of acute myeloid leukemia. [PDF]

Sci Rep
Hayashi H, Yamagiwa T, Kanda J, Ishikawa T, Sawa M, Miyahara Y, Tachibana T, Watanabe M, Ueda Y, Tsutsumi Y, Imada K, Fujiwara SI, Toubai T, Yoshifuji K, Hirata H, Kawabata H, Tsuji M, Wakita S, Yokoyama H, Kitano T, Murai K, Kataoka Y, Kawata E, Kimura SI, Yamamoto R, Miyao K, Nakayama D, Izumi A, Kawata T, Onda Y, Sakamoto T, Mizumoto C, Kitawaki T, Yamashita K, Yonezawa A, Kawakami T, Nakagawa S, Taniguchi R, Terada T, Takaori-Kondo A.   +39 more
europepmc   +1 more source

Latest advances in frontline CLL treatment from the 2025 ASH congress. [PDF]

Ann Hematol
Visentin A.
europepmc   +1 more source

Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia. [PDF]

Br J Haematol
Crespo-García E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, Martinez-Verbo L, Esteller M.   +5 more
europepmc   +1 more source

Population Pharmacokinetic Analyses and Exposure-Efficacy Relationships of Venetoclax in Chinese Pediatric Patients with Hematological Malignancy in a Real-World Setting. [PDF]

Drug Des Devel Ther
Zhao Y, Song X, Zhang L, Zhu Y, Chen J, Gong Y, Luo X, He H, Zhang X, Huang L.   +9 more
europepmc   +1 more source

High-Risk Chronic Lymphocytic Leukemia in a Young Adult Treated With Reduced-Dosage, Fixed-Duration Ibrutinib and Venetoclax. [PDF]

J Med Cases
Gutierrez CLD, Quero-Taggaoa AKH, Uy TCF, Veloso JAD.   +3 more
europepmc   +1 more source

Alizarin induces a multidirectional mechanism of anti-cancer action in cervical cancer and prostate cancer cells. [PDF]

Sci Rep
Trybus W, Trybus E, Król T.
europepmc   +1 more source